|
1
|
Nishio K, Nakamura T, Koh Y, Suzuki T,
Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin
Oncol. 11:109–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ikuta K, Takemura K, Sasaki K, Kihara M,
Nishimura M, Ueda N, Naito S, Lee E, Shimizu E and Yamauchi A:
Expression of multidrug resistance proteins and accumulation of
cisplatin in human non-small cell lung cancer cells. Biol Pharm
Bull. 28:707–712. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Triller N, Korosec P, Kern I, Kosnik M and
Debeljak A: Multidrug resistance in small cell lung cancer:
Expression of P-glycoprotein, multidrug resistance protein 1 and
lung resistance protein in chemo-naive patients and in relapsed
disease. Lung Cancer. 54:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Young LC, Campling BG, Voskoglou-Nomikos
T, Cole SP, Deeley RG and Gerlach JH: Expression of multidrug
resistance protein-related genes in lung cancer: Correlation with
drug response. Clin Cancer Res. 5:673–680. 1999.PubMed/NCBI
|
|
6
|
Lario Paredes A, Blanco García C, Elizondo
Echenique M and Lobo C: Expression of proteins associated with
multidrug resistance and resistance to chemotherapy in lung cancer.
Arch Bronconeumol. 43:479–484. 2007.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galimberti S, Marchetti A, Buttitta F,
Carnicelli V, Pellegrini S, Bevilacqua G and Petrini M: Multidrug
resistance related genes and p53 expression in human non small cell
lung cancer. Anticancer Res. 18:2973–2976. 1998.PubMed/NCBI
|
|
8
|
Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN
and Yu QZ: MDR1 single nucleotide polymorphisms predict response to
vinorelbine-based chemotherapy in patients with non-small cell lung
cancer. Respiration. 75:380–385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Y, Tang Y, Guo C, Wang J, Boral D and
Nie D: Nuclear receptors in the multidrug resistance through the
regulation of drug-metabolizing enzymes and transporters.
Biochemical Pharmacology. 83:1112–1126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harmsen S, Meijerman I, Beijnen JH and
Schellens JH: The role of nuclear receptors in pharmacokinetic
drug-drug interactions in oncology. Cancer Treat Rev. 33:369–380.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Omiecinski CJ, Vanden Heuvel JP, Perdew GH
and Peters JM: Xenobiotic metabolism, disposition and regulation by
receptors: From biochemical phenomenon to predictors of major
toxicities. Toxicol Sci. 120(Suppl 1): S49–S75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geick A, Eichelbaum M and Burk O: Nuclear
receptor response elements mediate induction of intestinal MDR1 by
rifampin. J Biol Chem. 276:14581–14587. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hernandez-Yanez M, Heymach JV and Zurita
AJ: Circulating biomarkers in advanced renal cell carcinoma:
Clinical applications. Curr Oncol Rep. 14:221–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pondugula SR and Mani S: Pregnane
xenobiotic receptor in cancer pathogenesis and therapeutic
response. Cancer Lett. 328:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mohr S and Liew CC: The peripheral-blood
transcriptome: New insights into disease and risk assessment.
Trends Mol Med. 13:422–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ban JJ, Jung KH, Chu K, Lee ST, Jeon D,
Park KI, Moon HJ, Kim H, Kim S, Lee SK and Roh JK: Profiles of
multidrug resistance protein-1 in the peripheral blood mononuclear
cells of patients with refractory epilepsy. PLoS One. 7:e369852012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valente RC, Capella LS, Nascimento CR,
Braga F, Echevarria-Lima J, Lopes AG and Capella MA: ABCB1
(P-glycoprotein) but not ABCC1 (MRP1) is downregulated in
peripheral blood mononuclear cells of spontaneously hypertensive
rats. Pflugers Arch. 456:359–368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Helsley RN, Sui Y, Ai N, Park SH, Welsh WJ
and Zhou C: Pregnane X eeceptor mediates dyslipidemia induced by
the HIV protease inhibitor amprenavir in mice. Mol Pharmacol.
83:1190–1199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Godoy P, Hewitt NJ, Albrecht U, Andersen
ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger
J, et al: Recent advances in 2D and 3D in vitro systems using
primary hepatocytes, alternative hepatocyte sources and
non-parenchymal liver cells and their use in investigating
mechanisms of hepatotoxicity, cell signaling and ADME. Arch
Toxicol. 87:1315–1530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Melguizo C, Prados J, Luque R, Ortiz R,
Rama AR, Caba O, Rodríguez-Serrano F, Álvarez PJ and Aránega A:
Modulation of multidrug resistance gene expression in peripheral
blood mononuclear cells of lung cancer patients and evaluation of
their clinical significance. Cancer Chemother Pharmacol.
71:537–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Melguizo C, Prados J, Luque R, Ortiz R,
Caba O, Alvarez PJ, Gonzalez B and Aranega A: Modulation of MDR1
and MRP3 gene expression in lung cancer cells after paclitaxel and
carboplatin exposure. Int J Mol Sci. 13:16624–16635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Synold TW, Dussalt I and Forman BM: The
orphan nuclear SXR coordinately regulates drug metabolism and
efflux. Nat Med. 7:584–590. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prados J, Melguizo C, Ortiz R, Perazzoli
G, Cabeza L, Alvarez PJ, Rodriguez-Serrano F and Aranega A: Colon
cancer therapy: Recent developments in nanomedicine to improve the
efficacy of conventional chemotherapeutic drugs. Anticancer Agents
Med Chem. 13:1204–1216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prados J, Melguizo C, Roldan H, Alvarez
PJ, Ortiz R, Arias JL and Aranega A: RNA interference in the
treatment of colon cancer. BioDrugs. 27:317–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clares B, Biedma-Ortiz RA, Sáez-Fernández
E, Prados JC, Melguizo C, Cabeza L, Ortiz R and Arias JL:
Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for
combined hyperthermia and chemotherapy against colon cancer. Eur J
Pharm Biopharm. 85:329–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harmsen S, Meijerman I, Maas-Bakker RF,
Beijnen JH and Schellens JH: PXR-mediated P-glycoprotein induction
by small molecule tyrosine kinase inhibitors. Eur J Pharm Sci.
48:644–649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiao E, Ji M, Wu J, Ma R, Zhang X, He Y,
Zha Q, Song X, Zhu LW and Tang J: Expression of the PXR gene in
various types of cancer and drug resistance. Oncol Lett.
5:1093–1100. 2013.PubMed/NCBI
|
|
28
|
Hoda RS: Non-gynecologic cytology on
liquid-based preparations: A morphologic review of facts and
artifacts. Diagn Cytopathol. 35:621–634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martín-Banderas L, Sáez-Fernández E,
Holgado MÁ, Durán-Lobato MM, Prados JC, Melguizo C and Arias JL:
Biocompatible gemcitabine-based nanomedicine engineered by flow
focusing for efficient antitumor activity. Int J Pharm.
443:103–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
